Current Location: Home >Research >Immix... recnac latceroloc ni 011-XMI r

Immix... recnac latceroloc ni 011-XMI r

2025-05-23 06:12:49 [Tech & Dev] Source:
Immix Biopharma (NASDAQ:IMMX) reported early interim data from a phase 1b/2a trial of IMX-110 in combination with Novartis (NYSE:NVS) and BeiGene's (NASDAQ:BGNE) tislelizumab to treat patients with ad... Stay informed with the latest.

(Editor in charge: Breaking News)

    Recommended Articles
    Popular Reads